Abstract: The activation of phospholipase C (PLC) is thought to have a key role in the cardiomyocyte response to several different hypertrophic agents such as norepinephrine, angiotensin II and endothelin-1. PLC activity results in the generation of diacylglycerol and inositol trisphosphate, which are downstream signal transducers for the expression of fetal genes, increased protein synthesis, and subsequent cardiomyocyte growth. In this article, we describe the signal transduction elements that regulate PLC gene expression. The discussion is focused on the norepinephrine-α<sub>1</sub>-adrenoceptor signaling pathway and downstream signaling processes that mediate an upregulation of PLC isozyme gene expression. Evidence is also indicated to demonstrate that PLC activities self-regulate the expression of PLC isozymes with the suggestion that PLC activities may be part of a coordinated signaling process for the perpetuation of cardiac hypertrophy. Accordingly, from the information provided, it is plausible that specific PLC isozymes could be targeted for the mitigation of cardiac hypertrophy.

Keywords: phospholipase C isozymes; cardiomyocytes; signal transduction; cardiac gene expression; cardiac cell growth; cardiac hypertrophy

1. Introduction

It is well established that cardiac hypertrophy is associated with concomitant alterations in the expression levels of many genes. In addition, cardiomyocyte growth is due to an increase in protein content in the cardiomyocyte as opposed to an increase in cell numbers because adult cardiomyocytes do not have the capacity to proliferate as they are terminally differentiated [1]. Accordingly, the cardiomyocyte hypertrophic response is characterized by increases in cardiomyocyte size, RNA concentration, and protein synthesis as well as expression of fetal genes including atrial natriuretic factor (ANF) [2–13] due to the activation of several transcription factors [14,15]. Furthermore, a transient activation of the c-Fos and c-Jun complex (AP-1) also occurs in the early response to hypertrophic stimuli [14,16]. In fact, cumulative evidence has determined that both AP-1 complex and ANF induce the activation of several hypertrophic genes [14,17–19].

The increases in c-Fos mRNA and protein synthesis in response to norepinephrine are attributed to the activation of the α<sub>1</sub>-adrenoceptor (AR) [14,18,20,21]. A transient increase of c-Jun expression has been reported in response to mechanical overload [22]. Cardiomyocyte transfection with a dominant negative c-Jun has been shown to prevent the increases in protein synthesis and atrial natriuretic peptide mRNA in response to the AR agonist, phenylephrine [23]. In contrast, a marked activation of the ANF gene promoter has been observed in cardiomyocytes overexpressing c-Jun [20]. On the other hand, pretreatment of neonatal rat cardiomyocytes, in vitro, with PLC antisense oligonucleotides was demonstrated to prevent the upregulation of c-Fos and c-Jun due to insulin-like growth factor-1 [24]. These authors suggested that signal transduction by specific phospholipase C (PLC) isozymes could have an important role in the regulation of these transcription factors.
The activation of PLC is considered a primary signaling event in the regulation of diverse cellular functions [25,26]. Several different agents, such as neurohormones and growth factors, induce phenotypic changes in cardiomyocytes that are characteristic of the hypertrophic response and activate PLC [27,28]. Mechanical stretching of isolated cardiomyocytes or in vivo due to pressure/volume overload also results in the activation of the PLC signal transduction pathway [4,29–31] as well as induces characteristic features of cardiac hypertrophy. Figure 1 depicts the norepinephrine-mediated signal transduction events that result in cardiomyocyte cell growth, for which PLC is an important and integral component. Indeed, the phosphorylation of target proteins [32], the activation of transcription factors, and subsequent gene expression [9,33] in the cardiomyocyte hypertrophic response to norepinephrine may all be initiated by PLC activation.

Figure 1. Norepinephrine-induced signal transduction resulting in cardiomyocyte hypertrophy. α1-AR, α1-adrenoceptors; Gαq, Gq protein alpha subunit; PLC, phospholipase C. There are several proteins that are phosphorylated such as ERK1/2, PKC, Ca2+/Calmodulin-dependent kinase, and JNK [32], which in turn phosphorylate and activate transcription factors such as c-Fos and c-Jun leading to the gene expression of PLC as well as the expression of fetal genes that are characteristic of cardiac hypertrophy [9,33].

Although animal models have facilitated in identifying alterations in gene expression during cardiac hypertrophy, the use of in vitro systems has permitted further delineation of the signal transduction processes and molecular events implicated in increasing cardiomyocyte growth during the response to different hypertrophic stimuli. Thus, in this
review, it is intended to describe changes in PLC isozyme gene and protein expression as well as isozyme activities in cardiac hypertrophy due to different etiologies and in isolated cardiomyocytes in response to norepinephrine. In addition, we also discuss the in vivo as well as in vitro signal transduction elements and the identity of the transcription factors that regulate PLC gene expression. Furthermore, the available evidence is presented to show that PLC regulates its own gene expression. Overall, the contention of this article is that PLC might constitute a mechanism for the perpetuation of the hypertrophic process and ultimately its transition to heart failure and may therefore be an important molecular and pharmacological target.

2. Regulation of Cardiac PLC Isozymes

There are now 13 families of PLC isozymes that are categorized into 6 classes; PLC β, δ, γ, ε, ζ, and η isozymes [34,35], and are known to be differentially expressed in mammalian cells [36]. Phosphoinositide-specific PLC activity results in the hydrolysis of membrane phosphatidylinositol-4,5-bisphosphate (PIP$_2$) to generate inositol-1,4,5-trisphosphate (IP$_3$) and 1,2-diacylglycerol (DAG) [37]. Both these lipid molecules activate downstream signal transduction events for cardiac hypertrophy. In this regard, the interaction of IP$_3$ with its receptors stimulates the release of Ca$^{2+}$ from intracellular stores, whereas DAG activates protein kinase C (PKC) isoforms. Although there is now a large body of information that has established the involvement of specific PKC isoforms in cardiomyocyte growth [38,39], IP$_3$/Ca$^{2+}$ are also considered to be important signaling elements for cardiac hypertrophy [6,9,40,41].

PLC β, δ, γ, and ε [42–47] are the major myocardial PLC isozymes and are known to be activated by different mediators including G proteins, tyrosine kinases, and calcium [48]. The PLC β family has four types of isozymes (β$_1$, β$_2$, β$_3$, and β$_4$) [36]. PLC β$_4$ has been reported to exhibit higher expression level in the heart relative to PLC β$_1$, β$_2$, and β$_3$ [49]. The mechanisms involved in the activation of PLC β$_1$ and PLC β$_3$ isozymes are the most well studied among PLC isozymes in the heart. In this regard, norepinephrine and other α$_1$-AR agonists are known to stimulate PLC β isozyme activities through Gqα [50]. In addition, unlike PLC β$_4$, PLC β$_1$-$β_3$ is also stimulated via the Gβγ dimer [51]. Furthermore, the Gβγ subunit can also directly activate PLC ε [52].

PLC γ$_1$ is localized in the cell cytosol and is regarded as the predominant cardiac PLC isozyme [53]. This isozyme is activated by GPCR and growth factor receptor tyrosine kinases, although a non-tyrosine kinase-mediated stimulation of PLC γ$_1$ has also been observed [54]. Indeed, some of our work has suggested the existence of a tyrosine kinase and Gqα subunit cross-talk in adult rat cardiomyocytes [55]. In contrast, PLC δ$_1$ is viewed to be the major PLC isozyme located at the sarcolemmal (SL) membrane. This has been attributed to the presence of basic amino acids in the N-terminal region of the pleckstrin homology domain of PLC δ$_1$, which have a strong affinity for membrane PIP$_2$ [56,57]. While intracellular Ca$^{2+}$ levels have been shown to modulate PLC δ$_1$ activity, a direct α$_1$-AR induced activation of PLC δ isozyme by the dimeric Gi$_n$ protein has also been reported [58,59].

3. Upregulation of PLC Isozymes in Pathological Cardiomyocyte Growth

Transgenic and In Vivo Models of Cardiac Hypertrophy

The upregulation of PLC has been established in several diverse transgenic mice and other animal models of cardiac hypertrophy. In this regard, the activation of PLC-mediated signal transduction in cardiac hypertrophy in stroke-prone spontaneously hypertensive rats has been reported [60,61]. In volume overload-induced cardiac hypertrophy subsequent to an arteriovenous shunt, specific increases in PLC β$_1$ and PLC γ$_1$ isozyme gene, protein contents, and activities [62,63] have been observed. A similar activation of PLC β$_3$ has been observed in pressure overload-induced cardiac hypertrophy due to aortic constriction in the rat [64]. In contrast, the activation of PKC isoforms has been observed in pressure overload cardiac hypertrophy in the guinea pig, subsequent to ligation of the descending
thoracic artery, without any changes in PLCβ1 and Gqα protein contents [65]. However, these investigators indicated that the stimulation of PKC isoforms could be a result of an increase in Gqα and PLCβ1 activities instead of an upregulation of their expression [66]; it should be mentioned that PLCβ1 activity was not measured in this study. Since mechanical stretch is an initiating feature for hypertrophy in response to hemodynamic overload, and that an increase in both Gqα and PLCβ1 activities has been reported in stretched cardiomyocytes [29,30] as well as increased sympathetic nervous activity [67] in pressure-overload hypertrophy, it is therefore highly conceivable that stimulation of the α2-AR increases PLCβ isoform activity in mechanical stress.

The stimulation of receptor-coupled Gqα in transgenic mouse models overexpressing Gqα results in cardiac hypertrophy [68–71], which potentially may be attributed to increases in PLC activity. However, the activation of PLC was found not to be associated with cardiac hypertrophy in two other different transgenic mouse lines expressing activated Gqα [72,73]. Although signal transduction mediated by specific PLC isoforms is an important component of the cardiomyocyte hypertrophic response, the abolition of signal transduction in PLCε (−/−) mice results in cardiac hypertrophy that has been attributed to an increase in sensitivity to isoproterenol [66,74]. While the individual role of the different PLC isoforms in pathological cardiomyocyte growth still remains to be fully understood, from the information provided, it is apparent that PLC is an important contributor to the signaling processes leading to cardiac hypertrophy.

4. Isolated Cardiomyocytes for Assessing the Hypertrophic Response

The generation of IP3 in neonatal cardiomyocytes has been observed in response to norepinephrine and is considered to be attributed to the α1-AR-mediated activation of PLCβ1 [75]. There are two splice variants of PLCβ1 in the heart, PLCβ1a and PLCβ1b, which differ in their C-terminal amino acid sequences [76]. While PLCβ1a is located in the cytosol, PLCβ1b is localized in the SL membrane, particularly in regions rich in caveolae (membrane lipid rafts), and where the α1-ARs are also localized [76]. Therefore, α1-AR-mediated signal transduction in response to norepinephrine can be considered to be due to PLCβ1b. As a consequence, targeting of PLCβ1b is considered to have the potential to attenuate the development and progression of cardiac hypertrophy [76]. Indeed, an increase in cardiomyocyte growth with a concomitant increase in the ratio of protein to DNA as well as an increase in ANF levels have been reported in neonatal cardiomyocytes overexpressing PLCβ1b [77]. These observations demonstrated the involvement of α1-AR-PLCβ1b in the hypertrophic response and further strengthened the viability of PLCβ1b as a target for prevention/restriction of cardiac hypertrophy [77]. As already mentioned, PLCβ4 is highly expressed in human left ventricular tissue and in view of its reported increase in mouse HL-1 cardiomyocytes exposed to different hypertrophic agents, it is conceivable that PLCβ4 may play a complementary role in the signal transduction processes for pathological cardiomyocyte growth [49].

Although there is a large body of evidence on the involvement of PLCβ isoforms in cardiac hypertrophy, the contribution of other myocardial PLC isoforms to the cardiomyocyte hypertrophic response is less defined, but information is now emerging. In this regard, depletion of PLCε with siRNA in neonatal cardiomyocytes has been observed to reduce the cardiomyocyte response to a variety of hypertrophic agents [74]. However, even though a reduction in PLCε was shown not to attenuate IP3 production, it was proposed that regionalized PLC activity was essential for this response.

Our attention has focused on determining the contribution of the different PLC isoforms in cardiac hypertrophy. Although the involvement of the α1-AR-PLC signaling axis has been confirmed by antagonism of the α1-AR with prazosin, as well as inhibition of PLC activity with a compound, U73122, subsequent studies have been conducted to dissect the signal transduction events and transcriptional parameters that influence the expression levels of the PLC genes [78–80]. The data presented in Table 1 show specific increases in the transcription factors, c-Fos and c-Jun in adult rat cardiomyocytes treated
with norepinephrine and with phentolamine; no changes in the other transcription factors (NFAT3, NFκB, MEF2C, and MEF2D) were observed [78]. These findings were suggestive of a specific and early upregulation of both c-Fos and c-Jun due to stimulation of the α1-AR under our experimental conditions.

Cardiomyocytes were treated with 5 µM norepinephrine (NE) or 1 µM phentolamine (PhE) for 2 h. Transcription factor mRNA levels were measured by semi-quantitative RT-PCR and the data are presented as a percentage of the control values. These values are means ± S.E. of 5 experiments conducted with 5 different cardiomyocyte preparations.

Table 1. Specific alterations in transcription factor gene expression in cardiomyocytes treated with norepinephrine and phenylephrine.

| Transcription Factor mRNA Level (% of Control) |
|-----------------------------------------------|
| NFAT3 (99 bp) | NFκB (124 bp) | MEF2C (92 bp) | MEF2D (105 bp) | c-Fos (74 bp) | c-Jun (163 bp) |
| Agonist |
| NE | 110 ± 8 | 112 ± 9 | 121 ± 11 | 113 ± 6 | 268 ± 12 * | 217 ± 6 * |
| PhE | 125 ± 11 | 109 ± 8 | 127 ± 8 | 130 ± 13 | 261 ± 7 * | 225 ± 8 * |

* Significantly different (p < 0.05) vs. control value. Information presented is based on the data in our paper [78].

Subsequent studies demonstrated that both c-Fos and c-Jun have a regulatory role in the expression of PLC isozymes [79]. In this regard, by employing gene silencing techniques, it was found that transfection of cardiomyocytes with c-Fos siRNA prevented the norepinephrine-induced increases in PLC β1 and PLC β3 mRNA levels, but did not affect the norepinephrine-induced increases in PLC γ1 and PLC δ1 gene expression (Table 2A). In addition, silencing of c-Jun with siRNA not only inhibited the norepinephrine-induced increases in PLC β1 and PLC β3 mRNA levels but also prevented the increase in PLC δ1 mRNA levels in response to norepinephrine. Similarly, silencing of c-Jun did not attenuate PLC γ1 gene expression in response to norepinephrine (Table 2A). Furthermore, knockdown of both c-Fos and c-Jun inhibited the norepinephrine-induced activation of PLC isozymes as determined by the formation of inositol phosphates (Table 2B). These data demonstrated differential transcriptional regulation of PLC isozymes [79].

Table 2. Inhibition of norepinephrine the increases in PLC isozyme gene expression (A) and activities (B) in response to norepinephrine in cardiomyocytes transfected with c-Fos and c-Jun siRNA.

A: PLC mRNA Levels (% of Control)

|          | β1 (114 bp) | β3 (230 bp) | γ1 (123 bp) | δ1 (190 bp) |
|----------|-------------|-------------|-------------|-------------|
| Agonist  |
| NE       | 219 ± 11 *  | 182 ± 18 *  | 168 ± 18 *  | 221 ± 18 *  |
| NE + cFos siRNA | 80 ± 21 # | 89 ± 11 #  | 160 ± 15 #  | 218 ± 17 #  |
| NE + cJun siRNA | 75 ± 19 # | 91 ± 9 #   | 170 ± 14 #  | 74 ± 8 #    |

B: Inositol Phosphates (pmol/min/mg Protein)

|          | PLC β1 | PLC β3 | PLC δ1 |
|----------|--------|--------|--------|
| Control  | 2.8 ± 0.6 | 4.1 ± 0.8 | 10.0 ± 1.4 |
| NE       | 6.8 ± 1.0 * | 7.0 ± 1.3 * | 17.1 ± 3.0 * |
| NE + cFos siRNA | 3.5 ± 0.7 # | 4.5 ± 0.8 # | 16.6 ± 2.4 |
| NE + cJun siRNA | 3.0 ± 0.8 # | 3.9 ± 0.9 # | 11.8 ± 2.6 # |

* Significantly different (p < 0.05) vs. control; # significantly different (p < 0.05) vs. NE. NE, norepinephrine; siRNA = small interfering RNA. Information presented is based on the data in our paper [79].

Since stimulation of the α1-AR was seen to result in a specific increase in the mRNA levels of both c-Fos and c-Jun, it is likely that α1-AR-PLC signal transduction is implicated in increases in c-Fos and c-Jun mRNA levels due to norepinephrine. It can be observed from Table 3 that both prazosin and U73122 blocked the increases in c-Fos and c-Jun mRNA levels
in cardiomyocytes exposed to norepinephrine [78,79]. To further verify the participation of PLC in modulating transcription factor expression levels, cardiomyocytes were transfected with PLC isozyme-specific siRNA.

Cardiomyocytes were transfected with or without 5 nM siRNA and treated with NE (5 μM) for 2 h. Cardiomyocytes without any treatment served as control. PLC mRNA levels were determined by semi-quantitative RT-PCR and data are presented as a percentage of the control value. PLC isozymes activities were determined by measuring the hydrolysis of [3H]-PIP2 and are expressed as pmol/min/mg protein of inositol phosphates formed. These values are means ± S.E. of 5 experiments conducted with 5 different cardiomyocyte preparations.

Table 3. Pharmacological and gene silencing interventions for the inhibition of increases in c-Fos and c-Jun gene expression levels in response to norepinephrine.

| Condition         | c-Fos mRNA Expression Levels | c-Jun mRNA Expression Levels |
|-------------------|------------------------------|------------------------------|
| NE                | 214 ± 23 *                   | 198 ± 20 *                   |
| +Prazosin         | 114 ± 11 *                   | 100 ± 8 *                    |
| +U73122           | 83 ± 8 *                     | 95 ± 11 *                    |
| +PLC β1 siRNA     | 110 ± 8 *                    | 85 ± 8 *                     |
| +PLC β3 siRNA     | 105 ± 7 *                    | 95 ± 11 *                    |
| +PLC γ1 siRNA     | 175 ± 25 *                   | 180 ± 13 *                   |
| +PLC δ1 siRNA     | 108 ± 7 *                    | 80 ± 7 *                     |

* Significantly different (p < 0.05) vs. control. # significantly different (p < 0.05) vs. NE. NE, norepinephrine; siRNA = small interfering RNA. Information presented is based on the data in our papers [78,79].

Cardiomyocytes were exposed to NE (5 μM) without and with prazosin (2 μM), U73122 (1 nM), or after transfection with 5 nM PLC isozyme siRNA for 2 h. c-Fos and c-Jun mRNA levels were determined by semi-quantitative RT-PCR and data are presented as a percentage of the control value. These values are means ± S.E. of 5 experiments conducted with 5 different cardiomyocyte preparations.

With the exception of silencing of PLC γ1, knockdown of PLC β1, β3, and δ1 genes was observed to prevent the increases in the mRNA levels of c-Fos and c-Jun (Table 3). These data indicated that the norepinephrine-α1-AR-mediated increases in c-Fos and c-Jun mRNA may involve signal transduction via some specific PLC isozymes.

The signaling events that regulate the expression levels of PLC isozyme genes were delineated through pharmacological and gene silencing interventions [79,80]. While prazosin and U73122 attenuated the increases in PLC isozyme gene expression in response to norepinephrine, silencing of the PLC gene with siRNA also prevented the norepinephrine-induced increases in PLC gene expression. In view of these observations, it was hypothesized that PLC activity can increase its own gene expression in response to stimulation with norepinephrine in adult cardiomyocytes (Table 4). Furthermore, it was demonstrated that PLC isozyme self-regulation of gene expression, may involve downstream PKC- and ERK1/2- signaling processes (Table 5 [80]).

Cardiomyocytes were exposed to NE (5 μM) without and with prazosin (2 μM), U73122 (1 nM), or after transfection with 5 nM PLC isozyme siRNA for 2 h. PLC isozyme mRNA levels were determined by semi-quantitative RT-PCR and data are presented as a percentage of the control value. These values are means ± S.E. of 5–10 experiments conducted with 5–10 different cardiomyocyte preparations.
Table 4. Attenuation of the increases in phospholipase C gene expression due to norepinephrine by pharmacological and gene silencing interventions.

| Condition       | β₁        | β₃        | γ₁        | δ₁        |
|-----------------|-----------|-----------|-----------|-----------|
| NE              | 201 ± 9 * | 188 ± 8 * | 181 ± 9 * | 159 ± 8 * |
| +Prazosin       | 99 ± 11 # | 102 ± 4 # | 120 ± 5 # | 90 ± 4 #  |
| +U73122         | 68 ± 5 #  | 80 ± 4 #  | 103 ± 11 #| 67 ± 12 # |
| +PLC β₁ siRNA   | 90 ± 8 #  | -         | -         | -         |
| +PLC β₃ siRNA   | -         | 80 ± 9 #  | -         | -         |
| +PLC γ₁ siRNA   | -         | -         | 61 ± 7 *  | -         |
| +PLC δ₁ siRNA   | -         | -         | -         | 60 ± 8 #  |

* Significantly different (p < 0.05) vs. control; # significantly different (p < 0.05) vs. NE. NE, norepinephrine; siRNA = small interfering RNA. Information presented is based on the data in our papers [79,80].

Table 5. PLC isozyme gene expression in adult rat cardiomyocytes treated with phorbol 12-myristate 13-acetate, bisindolylmaleimide, or PD98059.

| Treatment       | β₁        | β₃        | γ₁        | δ₁        |
|-----------------|-----------|-----------|-----------|-----------|
| PMA (µM)        |           |           |           |           |
| 10.1            | 118 ± 11  | 131 ± 8   | 110 ± 10  | 108 ± 10  |
| 1.0             | 190 ± 12 *| 183 ± 9 * | 176 ± 13 *| 161 ± 15 *|
| 10.0            | 175 ± 11 *| 171 ± 10 *| 130 ± 12 *| 123 ± 12 *|
| NE (µM)         |           |           |           |           |
| 5.0             | 223 ± 11 *| 192 ± 19 *| 186 ± 15 *| 193 ± 15 *|
| +Bis-1 (nM)     |           |           |           |           |
| 50              | 95 ± 10 # | 96 ± 9 #  | 111 ± 14 #| 100 ± 8 # |
| 100             | 83 ± 8 #  | 80 ± 12 # | 100 ± 10 #| 82 ± 9 #  |
| 200             | 82 ± 9 #  | 75 ± 6 #  | 82 ± 9 #  | 77 ± 9 #  |
| +PD98059 (nM)   |           |           |           |           |
| 2               | 107 ± 11 #| 90 ± 9 #  | 117 ± 14 #| 120 ± 11 #|
| 10              | 84 ± 9 #  | 87 ± 11 # | 103 ± 9 # | 94 ± 8 #  |
| 25              | 77 ± 8 #  | 82 ± 7 #  | 82 ± 11 # | 90 ± 12 # |

* Significantly different (p < 0.05) vs. control; # significantly different (p < 0.05) vs. NE. NE, norepinephrine; PMA, phorbol myristate acetate; Bis-1, bisindolylmaleimide. Information presented is based on the data in our paper [80].

Cardiomyocytes were exposed to different concentrations of PMA (0.1, 1.0, and 10.0 µM) and to NE (5 µM) without and with varying concentrations of Bis-1 (50, 100, and 200 nM) and PD98059 (2, 10, and 25 nM) for 2 h. PLC mRNA levels were determined by semi-quantitative RT-PCR and data are presented as a percentage of the control value. These values are means ± S.E. of 5 experiments conducted with 5 different cardiomyocyte preparations.

Indeed, while the PKC activator (phorbol myristate acetate, PMA) increased PLC gene expression, the PKC activity inhibitor (bisindolylmaleimide, Bis-1) markedly attenuated the norepinephrine-induced increases in PLC isozyme mRNA level. Similarly, blockade of ERK1/2 with PD98059 abolished PLC gene expression in response to norepinephrine. From the aforementioned, it is proposed that PLC activation is an early response to α₁-AR activation by norepinephrine and that subsequent signal transduction events that augment PLC gene expression and activities may constitute a sequence of cyclical events designed to perpetuate cardiac hypertrophy and facilitate its ultimate transition into heart failure (Figure 2).
Figure 2. Role of phospholipase C in the perpetuation of cardiomyocyte growth response to norepinephrine. DAG = sn-1,2-diacylglycerol; IP$_3$, inositol-1,4,5-trisphosphate. The response to increased levels of norepinephrine (input) is a cyclical process that produces an increase in the expression of PLC isozyme genes and subsequent higher generation of DAG and IP$_3$ and stimulation of the signal for cardiac hypertrophy (output). The activation and amplification of PLC isozymes ensure continuation of this cycle of events for continuation of abnormal hypertrophic growth due sustained exposure to high levels of norepinephrine.

5. Evidence for Regression of Abnormal Cardiomyocyte Growth by α$_1$-AR Blockade

From the above-mentioned discussion, it is evident that the α$_1$-AR-Gqα-PLC signal transduction pathway has an important contribution to the hypertrophic response to norepinephrine. Accordingly, there are some experimental studies that have demonstrated that blockade of the α$_1$-AR with prazosin mitigates the transition of cardiac hypertrophy to heart failure [81–85].

In addition, we have observed prazosin and metoprolol (a β$_1$-AR receptor blocker) to reverse cardiac remodeling in the failing rat heart [86,87]. Furthermore, labetalol, a non-selective β-AR blocker, has been reported to reverse cardiac hypertrophy [88,89].

Importantly, several clinical investigations have revealed the advantageous effects of α$_1$-AR antagonists including prazosin in failing hearts due to different etiologies [90–93]. It should be mentioned that while co-administration of prazosin and metoprolol in heart failure was observed not to exert any additive effects [94], the results of the COMET trial (Carvedilol or Metoprolol European Trial), revealed a greater benefit of carvedilol in heart failure than with metoprolol alone [95]. Taken together, these lines of evidence suggest that agents that exhibit a capability to block both α- and β-ARs can provide an improved outcome by attenuation of cardiac hypertrophy. However, it should be noted that the use of α$_1$-AR blockers in patients with heart failure has been reported to produce no improvement in the condition [96,97]. Nonetheless, signal transduction mediated by the α$_1$-AR-PLC pathway can be considered to play an essential contributory role in pathological cardiomyocyte growth. Furthermore, it can be proposed that the activation of this signaling pathway perpetuates cardiac hypertrophy that eventually progresses to heart failure. Although the literature has focused largely on antagonism the role of the It should be mentioned that in cardiomyocytes isolated from spontaneously hypertensive rats,
α₂-AR signaling is markedly attenuated [98]. Moreover, it has been suggested that α₂-AR-mediated signal transduction counterbalances PLC-mediated signaling [99] indicating that cardiac SL α₂-ARs may also be an important target [100] and potentially for the mitigation of cardiac hypertrophy.

6. Conclusions

We have extensively reviewed the literature regarding the involvement of phospholipid-mediated signal transduction mechanisms in different myocardial diseases [101–106], and recently the involvement of PLC in the cardiomyocyte hypertrophic response to norepinephrine [107] as well as the role of PLC in the catecholamine-induced increase in cardiomyocyte protein synthesis [108] has also been reviewed. In the present article, the activation of PLC and the regulation of its gene expression in cardiomyocyte hypertrophic response have been addressed. From the evidence provided, it can be suggested that the activation of specific PLC isoforms by norepinephrine is an important aspect of the signal transduction cascade that stimulates abnormal cardiomyocyte growth and that this pathway may constitute a sequence of cyclical actions that allow for the continuation of cardiac hypertrophy (Figure 2). There are several protein kinases that are activated by the PLC pathway, these include PKC, ERK1/2, and Ca²⁺/calmodulin-dependent kinase. These kinases have an important role as they, in turn, phosphorylate and activate some transcription factors including c-Fos and c-Jun that leads to PLC gene expression.

The reciprocal relationship between PLC activities and PLC gene expression is a characteristic feature that augments cardiac hypertrophy. It should be noted that it is not the intention of this review to exclude the role of the β₁-AR Gs-protein-adenyl cyclase system, which is largely responsible for initiating the development of cardiac hypertrophy. However, it is our contention that signal transduction through the α₁-AR-Gqα-PLC axis plays a critical and complementary role in the initial phase of abnormal cardiomyocyte growth, and that signal transduction through this pathway is more significant in the late stage of cardiac hypertrophy as the β₁-AR is downregulated at this phase. It should also be mentioned that while the focus of this review has been on the α₁-AR-Gqα-PLC, there are other GPCRs that mediate the hypertrophic response. In this regard, the angiotensin II receptor blocker losartan has been observed to diminish PLC gene expression with a concomitant regression of cardiac hypertrophy [62]. Accordingly, it can be suggested that PLC has the potential to be viewed as an additional target for limiting pathological cardiomyocyte growth.

Author Contributions: Conceptualization, P.S.T.; writing—original draft preparation, P.S.T.; responsibility for the final draft and the scientific background of the manuscript, N.S.D. and P.S.T. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: Infrastructural support for this project was provided by the St. Boniface Hospital Albrechtsen Research Centre.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Fiedler, B.; Wollert, K.C. Targeting calcineurin and associated pathways in cardiac hypertrophy and failure. Expert Opin. Ther. Targets 2005, 9, 963–973. [CrossRef] [PubMed]
2. Balakumar, P.; Jagadeesh, G. Multifarious molecular signaling cascades of cardiac hypertrophy: Can the muddy waters be cleared? Pharmacol. Res. 2010, 62, 365–383. [CrossRef] [PubMed]
3. Clerk, A.; Cullingford, T.E.; Fuller, S.J.; Giraldo, A.; Markou, T.; Pikkarainen, S.; Sugden, P.H. Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses. J. Cell Physiol. 2007, 212, 311–322. [CrossRef] [PubMed]
4. De Jonge, H.W.; Dekkers, D.H.; Houts muller, A.B.; Sharma, H.S.; Lamers, J.M. Differential signaling and hypertrophic responses in cyclically stretched vs endothelin-1 stimulated neonatal rat cardiomyocytes. *Cell Biochem. Biophys.* 2007, 47, 21–32. [CrossRef]

5. Haque, Z.K.; Wang, D.Z. How cardiomyocytes sense pathophysiological stresses for cardiac remodeling. *Cell. Mol. Life Sci.* 2017, 74, 983–1000. [CrossRef]

6. Hefti, M.A.; Harder, B.A.; Ep penberger, H.M.; Schaub, M.C. Signaling pathways in cardiac myocyte hypertrophy. *J. Mol. Cell. Cardiol.* 1997, 29, 2873–2892. [CrossRef]

7. Heineke, J.; Molkentin, J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. *Nat. Rev. Mol. Cell Biol.* 2006, 7, 589–600. [CrossRef]

8. Peter, A.K.; Bjerke, M.A.; Lein wand, L.A. Biology of the cardiac myocyte in heart disease. *Mol. Biol. Cell* 2016, 27, 2149–2160. [CrossRef]

9. Takano, A.P.; Senger, N.; Barreto-Chaves, M.L.M. The endocrinological component and signaling pathways associated to cardiac hypertrophy. *Mol. Cell. Endocrinol.* 2020, 518, 110972. [CrossRef]

10. Winkle, A.J.; Nassal, D.M.; Shaheen, R.; Thomas, E.; Mohta, S.; Gratz, D.; Weinberg, S.H.; Hund, T.J. Emerging therapeutic targets for cardiac hypertrophy. *Expert Opin. Ther. Adv. Med. Biol.* 2022, 6, 29–40. [CrossRef]

11. Freire, G.; Ocampo, C.; Ilbawi, N.; Griffin, A.J.; Gupta, M. Overt expression of AP-1 reduces alpha myosin heavy chain expression in rat ventricular myocytes. *Adv. Exp. Med. Biol.* 2015, 811, 1129–1143. [PubMed]

12. Jeong, M.Y.; Kinugawa, K.; Vinson, C.; Long, C.S. AFOs dissociates cardiac myocyte hypertrophy and expression of the pathological gene program. *Circulation* 2005, 111, 1645–1660. [CrossRef] [PubMed]

13. Montessuit, C.; Thorburn, A. Transcriptional activation of the glucose transporter GLUT1 in ventricular cardiac myocytes by hypertrophic agonists. *J. Biol. Chem.* 1999, 274, 9006–9012. [CrossRef]

14. Colella, M.; Grisan, F.; Robert, V.; Turner, J.D.; Thomas, A.P.; Pozzan, T. Ca2+ oscillation frequency decoding in cardiac cell hypertrophy: Role of calcineurin/NFAT as Ca2+ signal integrators. *Proc. Natl. Acad. Sci. USA* 2008, 105, 2859–2864. [CrossRef]

15. Gupta, S.; Young, D.; Maitra, R.K.; Gupta, A.; Popovic, Z.B.; Yong, S.L.; Mahajan, A.; Wang, Q.; Sen, S. Prevention of cardiac hypertrophy and heart failure by silencing of NF-kappaB. *J. Mol. Biol.* 2008, 375, 637–649. [CrossRef]

16. Robinson, E.L.; Drawnel, F.M.; Mehdi, S.; Archer, C.R.; Liu, W.; Okken haug, H.; Alkass, K.; Aros sen, J.M.; Nagaraju, C.K.; Sjaastad, I.; et al. MSK-mediated phosphorylation of histone H3 Ser28 couples MAPK signalling with early gene induction and cardiac hypertrophy. *Cells* 2022, 11, 604. [CrossRef] [PubMed]

17. Rosenzweig, A.; Halazon etis, T.D.; Seidman, J.G.; Seidman, C.E. Proximal regulatory domains of rat atrial natriuretic factor gene. *Circulation* 1991, 84, 1256–1265. [CrossRef]

18. Saadane, N.; Alpert, L.; Chalifour, L.E. Altered molecular response to adrenoreceptor-induced cardiac hypertrophy in Eg-1-deficient mice. *Am. J. Physiol. Heart Circ. Physiol.* 2000, 278, H796–H805. [CrossRef]

19. Aoki, H.; Richmond, M.; Izumo, S.; Sadoshima, J. Specific role of the extracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro. *Biochem. J.* 2000, 347, 275–284. [CrossRef] [PubMed]

20. Hannan, R.D.; West, A.K. Adrenergic agents, but not triiodo-L-thyronine induce c-fos and c-myc expression in the rat heart. *J. Mol. Cell. Cardiol.* 2007, 43, 465–478. [CrossRef] [PubMed]

21. Hannan, R.D.; Stennard, F.A.; West, A.K. Expression of c-fos and related genes in the rat heart in response to norepinephrine. *J. Mol. Cell. Cardiol.* 1993, 25, 1137–1148. [CrossRef] [PubMed]

22. Schunkert, H.; Jahn, L.; Izumo, S.; Apstein, C.S.; Lorell, B.H. Localization and regulation of c-fos and c-jun protooncogene induction by systolic wall stress in normal and hypertrophied rat hearts. *Proc. Natl. Acad. Sci. USA* 1991, 88, 11480–11484. [CrossRef] [PubMed]

23. Park, D.J.; Rho, H.W.; Rhee, S.G. CD3 stimulation causes phosphorylation of phospholipase C-γ1 on serine and tyrosine residues in a human T-cell line. *Proc. Natl. Acad. Sci. USA* 1991, 88, 5453–5456. [CrossRef]

24. Schnabel, P.; Mies, F.; Nohr, T.; Geisler, M.; Böhm, M. Differential regulation of phospholipase C-β isozymes in cardiomyocyte hypertrophy. *Biochim. Biophys. Res. Commun.* 2000, 275, 1–6. [CrossRef]

25. Katan, M.; Cockcroft, S. Phospholipase C families: Common themes and versatility in physiology and pathology. *Prog. Lipid. Res.* 2020, 80, 101065. [CrossRef]

26. Vines, C.M. Phospholipase C. *Adv. Exp. Med. Biol.* 2012, 740, 235–254.

27. Bai, H.; Wu, L.L.; Xing, D.Q.; Liu, J.; Zhao, Y.L. Angiotensin II induced upregulation of G αq/11, phospholipase C β3 and extracellular signal-regulated kinase 2 via angiotensin II type 1 receptor. *Chin. Med. J.* 2004, 117, 88–93.

28. Lamers, J.M.; Eskildsen-Helmond, Y.E.; Resink, A.M.; de Jonge, H.W.; Bezstarost i, K.; Sharma, H.S.; van Heugten, H.A. Endothelin-1-induced phosphorylation of phospholipase C-beta and D and protein kinase C isozyme signaling leading to hypertrophy in rat cardiomyocytes. *J. Cardiovasc. Pharmacol.* 1995, 26, S100–S103. [CrossRef]

29. Ruwhof, C.; Egas, J.M.; van Wamel, A.E.; van der Laarse, A. Signal transduction of mechanical stress in myocytes and fibroblasts derived from neonatal rat ventricles. *Neth. Heart J.* 2001, 9, 372–378.

30. Ruwhof, C.; van Wamel, J.T.; Noordzij, L.A.; Aydin, S.; Harper, J.C.; van der Laarse, A. Mechanical stress stimulates phospholipase C activity and intracellular calcium ion levels in neonatal rat cardiomyocytes. *Cell Calcium* 2001, 29, 73–83. [CrossRef]

31. Woodcock, E.A.; Grubb, D.R.; Filtz, T.M.; Marasco, S.; Luo, J.; McLeod-Dryden, T.J.; Kaye, D.M.; Sadoshima, J.; Du, X.J.; Wong, C.; et al. Selective activation of the “β” splice variant of phospholipase Cβ1 in chronically dilated human and mouse atria. *J. Mol. Cell. Cardiol.* 2009, 47, 676–683. [CrossRef] [PubMed]
32. Yan, K.; Wang, K.; Li, P. The role of post-translational modifications in cardiac hypertrophy. J. Cell. Mol. Med. 2019, 23, 3795–3807. [CrossRef] [PubMed]

33. Hong, J.-H.; Zhang, H.-G. Transcription factors involved in the development and prognosis of cardiac remodeling. Front. Pharmacol. 2022, 13, 828549. [CrossRef] [PubMed]

34. Harden, T.K.; Sondek, J. Regulation of phospholipase C isoforms by ras superfamily GTPases. Annu. Rev. Pharmacol. Toxicol. 2006, 46, 355–379. [CrossRef]

35. Suh, P.-G.; Ryu, S.O.; Choi, W.C.; Lee, K.Y.; Rhee, S.G. Monoclonal antibodies to three phospholipase C isoforms from bovine brain. J. Biol. Chem. 1988, 263, 14497–14504. [CrossRef]

36. Gresset, A.; Sondek, J.; Harden, T.K. The phospholipase C isoforms and their regulation. Subcell. Biochem. 2012, 58, 61–94.

37. Fukami, K.; Inanobe, S.; Kanemaru, K.; Nakamura, Y. Phospholipase C is a key enzyme regulating intracellular calcium and modulating the phosphoinositide balance. Prog. Lipid Res. 2010, 49, 429–437. [CrossRef]

38. Miao, L.N.; Pan, D.; Shi, J.; Du, J.P.; Chen, P.F.; Gao, J.; Yu, Y.; Shi, D.Z.; Guo, M. Role and mechanism of PKC-δ in cardiovascular disease. Current status and perspective. Front. Cardiovasc. Med. 2022, 9, 816369. [CrossRef]

39. Singh, R.M.; Cummings, E.; Pantos, C.; Singh, J. Protein kinase C and cardiac dysfunction: A review. Heart Fail. Rev. 2017, 22, 843–859. [CrossRef]

40. Barac, Y.D.; Zeevi-Levin, N.; Yaniv, G.; Reiter, I.; Milman, F.; Shilkrut, M.; Coleman, R.; Abassi, Z.; Binah, O. The 1,4,5-inositol trisphosphate pathway is a key component in Fas-mediated hypertrophy in neonatal rat ventricular myocytes. Cardiovasc. Res. 2005, 68, 75–86. [CrossRef]

41. Kockskämper, J.; Zima, A.V.; Roderick, H.L.; Pieske, B.; Blatter, L.A.; Bootman, M.D. Emerging roles of inositol 1,4,5-trisphosphate signaling in cardiac myocytes. J. Mol. Cell. Cardiol. 2008, 45, 128–147. [CrossRef] [PubMed]

42. Hansen, C.A.; Schroering, A.G.; Robishaw, J.D. Subunit expression of signal transducing G proteins in cardiac tissue: Implications for phospholipase C-β regulation. J. Mol. Cell. Cardiol. 1995, 27, 471–484. [CrossRef]

43. Schnabel, P.; Gäs, H.; Nohr, T.; Camps, M.; Böhm, M. Identification and characterization of G protein-regulated phospholipase C-δ in human myocardium. J. Mol. Cell. Cardiol. 1996, 28, 2419–2427. [CrossRef]

44. Smrcka, A.V.; Brown, J.H.; Holz, G.G. Role of phospholipase C in physiological phosphoinositide signaling networks. Cell Signal. 2012, 24, 1333–1343. [CrossRef] [PubMed]

45. Suh, P.G.; Ryu, S.H.; Moon, K.H.; Suh, H.W.; Rhee, S.G. Cloning and sequence of multiple forms of phospholipase C-δ1. Mol. Cell. Biochem. 2010, 337, 167–173. [CrossRef]

46. Suh, P.G.; Rhee, S.G. Cloning and sequence of multiple forms of phospholipase C-δ1. Mol. Cell. Biochem. 2010, 337, 167–173. [CrossRef] [PubMed]

47. Wolf, R.A. Specific expression of phospholipase C-δ1 and γ1 by adult cardiac ventricular myocytes. Circulation 1993, 88 (Suppl. 1), I-241.

48. Nakamura, Y.; Fukami, K. Regulation and physiological functions of mammalian phospholipase C. J. Biochem. 2017, 161, 315–321. [CrossRef]

49. Otaegui, D.; Querejeta, R.; Arrieta, A.; Lazcano, A.; Bidaurrazaga, A.; Arriandiaga, J.R.; Aldazabal, P.; Garro, M.A. Phospholipase Cβ4 isozyme is expressed in human, rat, and murine heart left ventricles and in HL-1 cardiomyocytes. Mol. Cell. Biochem. 2010, 337, 167–173. [CrossRef]

50. Rhee, S.G. Regulation of phosphoinositide-specific phospholipase C. Annu. Rev. Biochem. 2001, 70, 281–312. [CrossRef]

51. Lee, C.W.; Lee, K.H.; Lee, S.B.; Park, D.; Rhee, S.G. Regulation of phospholipase C-β4 by ribonucleotides and the alpha subunit of Gq. J. Biol. Chem. 1994, 269, 25335–25338. [CrossRef]

52. Madukwe, J.C.; Garland-Kuntz, E.E.; Lyon, A.M.; Smrcka, A.V. G protein βγ subunits directly interact with and activate phospholipase Cδ. J. Biol. Chem. 2018, 293, 6387–6397. [CrossRef]

53. Cockcroft, S.; Thomas, G.M. Inositol-lipid-specific phospholipase C isozymes and their differential regulation by receptors. Biochem. J. 1992, 288, 1–14. [CrossRef] [PubMed]

54. Sekiya, F.; Bae, Y.S.; Rhee, S.G. Regulation of phospholipase C-α isozymes: Activation of phospholipase C-α γ in the absence of tyrosine-phosphorylation. Chem. Phys. Lipids. 1999, 98, 3–11. [CrossRef]

55. Tappia, P.S.; Padua, R.R.; Panagia, V.; Kardami, E. Fibroblast growth factor-2 stimulates phospholipase Cβ in adult cardiomyocytes. Biochem. Cell. Biol. 1999, 77, 569–575. [CrossRef]

56. Tall, E.; Dormán, G.; García, P.; Runnels, L.; Shah, S.; Chen, J.; Profit, A.; Gu, Q.M.; Chaudhary, A.; Prestwich, G.D.; et al. Phosphoinositide binding specificity among phospholipase C isoforms as determined by photo-cross-linking to novel substrate and product analogs. Biochemistry 1997, 36, 7239–7248. [CrossRef]

57. Yagisawa, H.; Sakuma, K.; Paterson, H.F.; Cheung, R.; Allen, V.; Hirata, H.; Watanabe, Y.; Hirata, M.; Williams, R.L.; Katán, M. Replacements of single basic amino acids in the pleckstrin homology domain of phospholipase C-δ alter the ligand binding, phospholipase activity, and interaction with the plasma membrane. J. Biol. Chem. 1998, 273, 417–424. [CrossRef]

58. Dupuis, M.; Houdeau, E.; Mhaouty-Kodja, S. Increased potency of α1-adrenergic receptors to induce inositol phosphates production correlates with the up-regulation of α1d/Gh α/phospholipase C δ1 signaling pathway in term rat myometrium. Reproduction 2008, 135, 55–62. [CrossRef]
59. Lin, Y.F.; Yeh, T.S.; Chen, S.F.; Tsai, Y.H.; Chou, C.M.; Yang, Y.Y.; Huang, H.M. Nonmuscle myosin II A (myosin heavy polypeptide 9): A novel class of signal transducer mediating the activation of Gαq/phospholipase C-β1 pathway. Endocrinology 2010, 151, 876–885. [CrossRef]

60. Kawaguchi, H.; Sano, H.; Iizuka, K.; Okada, H.; Kudo, T.; Kageyama, K.; Muramoto, S.; Murakami, T.; Okamoto, H.; Mochizuki, N. Phosphatidylinositol metabolism in hypertrophic rat heart. Circ. Res. 1993, 72, 966–972. [CrossRef]

61. Shoki, M.; Kawaguchi, H.; Okamoto, H.; Sano, H.; Sawa, H.; Kudo, T.; Hirao, N.; Sakata, Y.; Yasuda, H. Phosphatidylinositol and inositolphosphate metabolism in hypertrophied rat heart. Jpn. Circ. J. 1992, 56, 142–147. [CrossRef] [PubMed]

62. Dent, M.R.; Aroutiounova, N.; Dhall, N.S.; Tappia, P.S. Losartan attenuates phospholipase C isozyme gene expression in hypertrophied hearts due to volume overload. J. Cell. Mol. Med. 2006, 10, 470–479. [CrossRef] [PubMed]

63. Dent, M.R.; Dhall, N.S.; Tappia, P.S. Phospholipase C gene expression, protein content and activities in cardiac hypertrophy and heart failure due to volume overload. Am. J. Physiol. 2004, 282, H719–H727. [CrossRef]

64. Wu, J.; Zhang, C.; Liu, C.; Zhang, A.; Li, A.; Zhang, J.; Zhang, H. Aortic constriction induces hypertrophy and cardiac hypertrophy via (pro)renin receptor activation and the PLC-β3 signaling pathway. Mol. Med. Rep. 2019, 19, 573–580. [CrossRef] [PubMed]

65. Jalili, T.; Takeishi, Y.; Song, G.; Ball, N.A.; Howles, G.; Walsh, R.A. PKC translocation without changes in Gαq abundance in cardiac hypertrophy and failure. Am. J. Physiol. 1999, 277, H2298–H2304. [PubMed]

66. Wang, H.; Oestreich, E.A.; Maekawa, N.; Bullard, T.A.; Vikstrom, K.L.; Dirksen, R.T.; Kelley, G.G.; Blaxall, B.C.; Smrcka, A.V. Phospholipase Cζ modulates β-adrenergic receptor-dependent cardiac contraction and inhibits cardiac hypertrophy. Circ. Res. 2005, 97, 1305–1313. [CrossRef] [PubMed]

67. Ganguly, P.K.; Lee, S.L.; Beamish, R.E.; Dhall, N.S. Altered sympathetic system and adrenoceptors during the development of cardiac hypertrophy. Am. Heart J. 1989, 118, 520–525. [CrossRef]

68. Adams, J.W.; Sakata, Y.; Davis, M.G.; Sah, V.P.; Wang, Y.; Liggett, S.B.; Chien, K.R.; Brown, J.H.; Dorn, G.W., 2nd. Enhanced Gαq signaling: A common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc. Natl. Acad. Sci. USA 1998, 95, 10140–10145. [CrossRef] [PubMed]

69. D’Angelo, D.D.; Sakata, Y.; Lorenz, J.N.; Boivin, G.P.; Walsh, R.A.; Liggett, S.B.; Dorn, G.W., 2nd. Transgenic Gαq overexpression induces cardiac contractile failure in mice. Proc. Natl. Acad. Sci. USA 1997, 94, 8121–8126. [CrossRef]

70. Sakata, Y.; Hoit, B.D.; Liggett, S.B.; Walsh, R.A.; Dorn, G.W., 2nd. Decompensation of pressure-overload hypertrophy in Gαq-overexpressing mice. Circulation 1998, 97, 1488–1495. [CrossRef]

71. Sussman, M.A.; Welch, S.; Walker, A.; Klevitsky, R.; Hewett, T.E.; Price, R.L.; Schaefer, E.; Yager, K. Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. J. Clin. Investig. 2000, 105, 875–886. [CrossRef] [PubMed]

72. Mende, U.; Kagen, A.; Cohen, A.; Aramburu, J.; Schoen, F.J.; Neer, E.J. Transient cardiac expression of constitutively active Gαq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc. Natl. Acad. Sci. USA 1998, 95, 13893–13898. [CrossRef] [PubMed]

73. Mende, U.; Semsarian, C.; Martins, D.C.; Kagen, A.; Dovy, C.; Schoen, F.J.; Neer, E.J. Dilated cardiomyopathy in two transgenic mouse lines expressing activated G protein β2. Circulation 2001, 103, 1477–14791. [PubMed]

74. Zhang, L.; Malik, S.; Kelley, G.G.; Kapiloff, M.S.; Smrcka, A.V. Phospholipase Cζ scaffolds to muscle-specific A kinase anchoring protein (mAKAPβ) and integrates multiple hypertrophic stimuli in cardiac myocytes. J. Biol. Chem. 2011, 286, 23012–23021. [CrossRef] [PubMed]

75. Arthur, J.F.; Matkovich, S.J.; Mitchell, C.J.; Biden, T.J.; Woodcock, E.A. Evidence for selective coupling of α1-adrenergic receptors to phospholipase C-β1 in rat neonatal cardiomyocytes. J. Biol. Chem. 2001, 276, 37341–37346. [CrossRef] [PubMed]

76. Grubb, D.R.; Vasilevski, O.; Huynh, H.; Woodcock, E.A. The extreme C-terminal region of phospholipase C-β1 determines subcellular localization and function; the “b” splice variant mediates alpha1-adrenergic receptor responses in cardiomyocytes. FASEB J. 2008, 22, 2768–2774. [CrossRef]

77. Filtz, T.M.; Grubb, D.R.; McLeod-Dryden, T.J.; Luo, J.; Woodcock, E.A. Gq-initiated cardiomyocyte hypertrophy is mediated by phospholipase Cβ1. FASEB J. 2009, 23, 3564–3570. [CrossRef] [PubMed]

78. Singal, T.; Dhall, N.S.; Tappia, P.S. Regulation of c-Fos and c-Jun gene expression by phospholipase C activity in adult cardiomyocytes. Mol. Cell. Biochem. 2009, 327, 229–239. [CrossRef] [PubMed]

79. Singal, T.; Dhall, N.S.; Tappia, P.S. Reciprocal regulation of transcription factors and PLC isozyme gene expression in adult cardiomyocytes. J. Cell. Mol. Med. 2010, 14, 1824–1835. [CrossRef] [PubMed]

80. Singal, T.; Dhall, N.S.; Tappia, P.S. Norepinephrine-induced changes in gene expression of phospholipase C in cardiomyocytes. J. Mol. Cell. Cardiol. 2006, 41, 126–137. [CrossRef]

81. Giles, T.D.; Sander, G.E.; Thomas, M.G.; Quiroz, A.C. α-adrenergic mechanisms in the pathophysiology of left ventricular heart failure-An analysis of their role in systolic and diastolic dysfunction. J. Mol. Cell. Cardiol. 1996, 18, 33–43. [CrossRef]

82. Motz, W.; Klepzig, M.; Strauer, B.E. Regression of cardiac hypertrophy: Experimental and clinical results. J. Cardiovasc. Pharmacol. 1987, 10, S148–S152. [PubMed]

83. Prasad, K.; O’Neil, C.L.; Bharadwaj, B. Effect of prolonged prazosin treatment on hemodynamic and biochemical changes in the dog heart due to chronic pressure overload. Jpn. Heart J. 1984, 25, 461–476. [CrossRef] [PubMed]
84. Strauer, B.E.; Bayer, F.; Brecht, H.M.; Motz, W. The influence of sympathetic nervous activity on regression of cardiac hypertrophy. J. Hypertens. Suppl. 1985, 3, S39–S44.

85. Strauer, B.E. Progression and regression of heart hypertrophy in arterial hypertension: Pathophysiology and clinical aspects. Z. Kardiol. 1995, 74, 171–178.

86. Babick, A.; Elimban, V.; Dhalla, N.S. Reversal of cardiac remodeling and subcellular defects by prazosin in heart failure due to myocardial infarction. J. Clin. Exp. Cardiol. 2012, 5, 1–7. [CrossRef]

87. Babick, A.; Elimban, V.; Zieroth, S.; Dhalla, N.S. Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction. J. Cell Physiol. 2013, 228, 2063–2070. [CrossRef]

88. Massart, P.E.; Donckier, J.; Kyselovic, J.; Godfraind, T.; Heyndrickx, G.R.; Wilo, M. Carvedilol and lacidipine prevent cardiac hypertrophy and endothelin-1 gene expression after aortic banding. Hypertension 1999, 34, 1197–1201. [CrossRef] [PubMed]

89. Rosendorff, C. Beta-blocking agents with vasodilator activity. J. Hypertens. Suppl. 1993, 11, S37–S40. [CrossRef] [PubMed]

90. Antani, J.A.; Antani, N.J.; Nanivadekar, A.S. Prazosin in chronic congestive heart failure due to ischemic heart disease. Clin. Cardiol. 1991, 14, 495–500. [CrossRef]

91. Colucci, W.S.; Wynne, J.; Holman, B.L.; Braunwald, E. Long-term therapy of heart failure with prazosin: A randomized double blind trial. Am. J. Cardiol. 1980, 45, 337–344. [CrossRef]

92. Goldman, S.A.; Johnson, L.L.; Escala, E.; Cannon, P.; Weiss, M.B. Improved exercise ejection fraction with long-term prazosin therapy in patients with heart failure. Am. J. Med. 1980, 68, 36–42. [CrossRef]

93. Gomes, M.E.; Mulder, A.; Bellers, L.; Escala, E.; Cannon, P.; Weiss, M.B. Impact of α1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure. JAMA 2000, 283, 1967–1975. [CrossRef]

94. Dhalialiwal, A.S.; Habib, G.; Deswal, A.; Verduzzo, M.; Souchez, J.; Ramasubbu, K.; Aguilar, D.; Ma, T.S.; Jneid, H.M.; Bolos, M.; et al. Impact of α1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure. Am. J. Cardiol. 2009, 104, 270–275. [CrossRef]

95. Kokoz, Y.M.; Evdokimovskii, E.V.; Maltsev, A.V.; Nenov, M.N.; Nakipova, O.V.; Averin, A.S.; Pimenov, O.Y.; Teplov, I.Y.; Berezhnov, A.V.; Reyes, S.; et al. Sarcollemmal α2-adrenoceptors control protective cardiomyocyte-delimited sympathoadrenal response. J. Mol. Cell. Cardiol. 2016, 100, 9–20. [CrossRef]

96. Alekseev, A.E.; Park, S.; Pimenov, O.Y.; Reyes, S.; Terzic, A. Sarcollemmal α2-adrenoceptors in feedback control of myocardial response to sympathetic challenge. Pharmacol. Ther. 2019, 197, 179–190. [CrossRef]

97. Maltsev, A.V.; Kokoz, Y.M.; Evdokimovskii, E.V.; Pimenov, O.Y.; Reyes, S.; Alekseev, A.E. Alpha-2 adrenoceptors and imidazoline receptors in cardiomyocytes mediate counterbalancing effect of agmatine on NO synthesis and intracellular calcium handling. J. Mol. Cell. Cardiol. 2014, 68, 66–74. [CrossRef] [PubMed]

98. Dhalialiwal, A.S.; Xu, Y.J.; Sheu, S.S.; Tappia, P.S.; Panagia, V.; Phosphatidic acid: A potential signal transducer for cardiac hypertrophy. J. Mol. Cell. Cardiol. 1997, 29, 2856–2871. [CrossRef] [PubMed]

99. Tappia, P.S. Phospholipid-mediated signaling systems as novel targets for treatment of heart disease. Can. J. Physiol. Pharmacol. 2007, 85, 25–41. [CrossRef] [PubMed]

100. Tappia, P.S.; Asemu, G.; Rodriguez-Leyva, D. Phospholipase C as a potential target for cardioprotection during oxidative stress. Can. J. Physiol. Pharmacol. 2010, 88, 249–263. [CrossRef]

101. Tappia, P.S.; Dent, M.R.; Dhalla, N.S. Oxidative stress and redox regulation of phospholipase D in myocardial disease. Free Radic. Biol. Med. 2006, 41, 349–361. [CrossRef] [PubMed]

102. Tappia, P.S.; Dhalla, N.S. Mechanisms for the defects in phospholipid signal transduction in diabetic cardiomyopathy. Indian J. Biochem. Biophys. 2014, 51, 431–440. [PubMed]

103. Tappia, P.S.; Singal, T. Phospholipid-mediated signaling and heart disease. Subcell. Biochem. 2008, 49, 299–324. [PubMed]

104. Tappia, P.S.; Elimban, V.; Dhalla, N.S. Involvement of phospholipase C in the norepinephrine—Induced hypertrophic response in cardiomyocytes. Scr. Med. 2022, 53, 149–157. [CrossRef]

105. Tappia, P.S.; Ramjiawan, B.; Dhalla, N.S. Role of phospholipase C in catecholamine-induced increase in myocardial protein synthesis. Can. J. Physiol. Pharmacol. 2022, in press. [CrossRef]